S&P 500   5,064.96 (+0.06%)
DOW   37,939.54 (+0.54%)
QQQ   431.32 (+0.06%)
PFE   25.88 (-0.12%)
PYPL   62.86 (-1.02%)
XOM   118.90 (-0.65%)
S&P 500   5,064.96 (+0.06%)
DOW   37,939.54 (+0.54%)
QQQ   431.32 (+0.06%)
PFE   25.88 (-0.12%)
PYPL   62.86 (-1.02%)
XOM   118.90 (-0.65%)
S&P 500   5,064.96 (+0.06%)
DOW   37,939.54 (+0.54%)
QQQ   431.32 (+0.06%)
PFE   25.88 (-0.12%)
PYPL   62.86 (-1.02%)
XOM   118.90 (-0.65%)
S&P 500   5,064.96 (+0.06%)
DOW   37,939.54 (+0.54%)
QQQ   431.32 (+0.06%)
PFE   25.88 (-0.12%)
PYPL   62.86 (-1.02%)
XOM   118.90 (-0.65%)
Free Trial
NASDAQ:CBIO

Catalyst Biosciences (CBIO) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)
Free CBIO Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.34
▼
$7.67
52-Week Range
N/A
Volume
32,246 shs
Average Volume
763,526 shs
Market Capitalization
$291.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisDividendEarningsOwnershipSocial MediaSustainability
CBIO stock logo

About Catalyst Biosciences Stock (NASDAQ:CBIO)

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

CBIO Stock News Headlines

February 10, 2024 | seekingalpha.com
Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
January 5, 2024 | markets.businessinsider.com
Buy Rating Backed by Pivotal Trial Catalyst and Novel Drug Delivery Platform for Cellectar Biosciences
April 16, 2024 | InvestorPlace (Ad)
Elon Musk’s ChatGPT Could Soon Mint New Millionaires
Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.
November 1, 2023 | businesswire.com
Biocom California Names the Eighth Annual Life Science Catalyst Award Winners
October 30, 2023 | finance.yahoo.com
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split
October 23, 2023 | ft.com
General Catalyst in German VC tie-up as part of European tech push
October 18, 2023 | foxnews.com
'Blind Side' author Michael Lewis suggests catalyst behind Michael Oher lawsuit: 'Violence and aggression'
August 23, 2023 | finance.yahoo.com
Is Catalyst Biosciences (CBIO) Significantly Overvalued?
April 16, 2024 | InvestorPlace (Ad)
Elon Musk’s ChatGPT Could Soon Mint New Millionaires
Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.
August 22, 2023 | investing.com
Catalyst Biosciences (CBIO) Earnings Dates & Reports
June 9, 2023 | finance.yahoo.com
CBIO - Catalyst Biosciences, Inc.
April 28, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHBI, CBIO, TA, ASRT
April 3, 2023 | finance.yahoo.com
Catalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 months
March 31, 2023 | insidermonkey.com
5 Cheap Healthcare Stocks to Buy in 2023
March 31, 2023 | markets.businessinsider.com
Raymond James Sticks to Its Hold Rating for Catalyst Biosciences (CBIO)
March 29, 2023 | finance.yahoo.com
12 Cheap Healthcare Stocks to Buy in 2023
March 9, 2023 | prnewswire.com
CATALYST BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIO
February 28, 2023 | msn.com
Catalyst Biosciences Shares Are Rallying: What's Driving The Action?
February 28, 2023 | finance.yahoo.com
Catalyst Biosciences Provides Corporate Update
February 27, 2023 | finance.yahoo.com
GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology
February 5, 2023 | morningstar.com
Catalyst/Millburn Hedge Strategy I
January 19, 2023 | insidermonkey.com
5 Stocks with the Lowest PE Ratio
January 4, 2023 | prnewswire.com
STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Catalyst Biosciences, Inc. - CBIO
December 29, 2022 | wsj.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Catalyst Biosciences, Inc. Merger
December 29, 2022 | benzinga.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, BLI, ISO, CBIO
December 28, 2022 | benzinga.com
CBIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Catalyst Biosciences, Inc. Is Fair to Shareholders
November 16, 2022 | finance.yahoo.com
Catalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)
See More Headlines
Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/17/2023
Today
4/16/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBIO
CUSIP
87611R30
CIK
1124105
Web
www.catalystbiosciences.com
Phone
(650) 871-0761
Fax
336-480-2107
Employees
7
Year Founded
2003

Profitability

EPS (Most Recent Fiscal Year)
($1.38)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,240,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-364.68%
Return on Assets
-281.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.88
Quick Ratio
2.88

Sales & Book Value

Annual Sales
$790,000.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.78) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
37,980,000
Free Float
36,869,000
Market Cap
$291.29 million
Optionable
Optionable
Beta
1.05

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Nassim Usman Ph.D. (Age 63)
    President, CEO & Director
    Comp: $1.75M
  • Ms. Seline E. Miller CPA (Age 54)
    Senior VP of Finance, Interim Chief Financial & Principal Accounting Officer
    Comp: $707.55k
  • Ms. Ana Kapor
    Senior Director of Investor Relations & Corporate Communications

Key Competitors

View All Competitors

CBIO Stock Analysis - Frequently Asked Questions

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) posted its quarterly earnings data on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07).

When did Catalyst Biosciences' stock split?

Catalyst Biosciences's stock reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Imunon (CLSN).

This page (NASDAQ:CBIO) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
The Greatest Bull Market in Crypto History…
Weiss Ratings